Multiple Myeloma: a Retrospective Analysis of 61 Patients from a Tertiary Care Center

  • Sultan, Sadia (Department of Hematology and Blood Bank, Liaquat National Hospital and Medical College) ;
  • Irfan, Syed Mohammed (Department of Hematology and Blood Bank, Liaquat National Hospital and Medical College) ;
  • Parveen, Saira (Department of Hematology and Blood Bank, Liaquat National Hospital and Medical College) ;
  • Ali, Hamza (Liaquat National Medical College) ;
  • Basharat, Maria (Liaquat National Medical College)
  • Published : 2016.06.01


Background: Multiple myeloma (MM) is an acquired clonal B-cell malignancy which primarily affects elderly individuals with an annual incidence of approximately 1% of all malignancies. Our aim is to study demographic and clinicopathological features of adult Pakistani MM patients at presentation. Materials and Methods: This single centre retrospective study extended from January 2010 to December 2014. Data were retrieved from the patients' maintained records on predetermined performa. Results: Overall, 61 patients were diagnosed at our institution with MM during the study period. There were 43 males and 18 females. Age ranged between 34 and 81 years with a mean of $56.1{\pm}12.8$ and a median of 57 years. The male to female ratio was ~2:1. Common presenting complaints included fatigue (81.9%), backache (80.3%) and bone pain (67.2%). Physical findings revealed pallor (44.2%) as a presenting clinical feature. The mean hemoglobin value was $8.9{\pm}1.7g/dl$ with a mean MCV of $85.3{\pm}11.0fl$. Severe anemia with hemoglobin <8.5 gm/dl was seen in 40.9%. The mean total leukocyte count was $8.9{\pm}8.2{\times}10^9/l$, the ANC was $5.0{\pm}3.1{\times}10^9/l$ and the mean platelet count was $188.4{\pm}150.6{\times}10^9/l$. Conclusions: MM in Pakistani patients is seen in a relatively young population with male preponderance. The majority of patients present with symptomatic anemia and backache to seek medical attention. However, clinico-pathological features appear comparable to the published literature.


  1. Basit A, Siddiqui N, Hameed A, et al (2014). Factors affecting outcome of patients with multiple myeloma. J Ayub Med Coll Abottabad, 26, 376-9.
  2. Eriksson M, Karisson M (1992). Occupational and other environ mental factors and multiple niycolma: a population based case-control study. Br1, Ind Med, 49, 95-103.
  3. Inam ullah, Raziq F, Tahir M, Wazir R, Rafiq A (2010). Hematological Presentation of Multiple Myeloma in Khyber Pakhtunkhwa. Gomal J Med Sciences, 8, 130-3.
  4. Kaur P, Shah BS, Baja P (2014). Multiple myeloma: a clinical and pathological profile. Gulf J Oncolog, 1, 14-20.
  5. Kyle RA, Gertz MA, Witzig TE, et al (2003). Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clinic Proc, 78, 21-33.
  6. Landgren O, Weiss BM (2009). Patterns of monoclonal gammopathy of undetermined significance and multiple myeloma in various ethnic/racial groups: support for genetic factors in pathogenesis. Leukemia, 23, 1691-7.
  7. McKenna RW, Kyle RA, Kuehl WM, et al (2008). WHO classification of tumours of haemopoietic and lymphoid tissues. Lyon: International Agency Res Cancer, 202.
  8. Mehdi WA, Zainulabdeen JA, Mehde AA (2013). Investigation of the antioxidant status in multiple myeloma patients: effects of therapy. Asian Pac J Cancer Prev, 14, 3663-7.
  9. Mansoor S, Siddiqui I, Adil S, Kakapeto GN, Fatmi Z (2005). Frequency of hypercalcemia in patients of multiple myeloma in Karachi. J Coll Physicians Surg Pak, 15, 409-12.
  10. Mansoor S, Siddiqui I, Adil S, et al (2007). Anion gap among patients of multiple myeloma and normal individuals. Clin Biochem, 40, 226-9.
  11. Mohammadi M, Cao Y, Glimelius I, et al (2015) .The impact of comorbid disease history on all-cause and cancer-specific mortality in myeloid leukemia and myeloma - a Swedish population-based study. BMC Cancer, 15, 850.
  12. Omoti CE, Nwannadi AI, Obieche JC, Olu-Eddo AN (2012). The epidemiological features of lymphoid malignancies in Benin City, Nigeria: a 15 years study. Pan Afr Med J, 11, 10.
  13. Rajkumar SV (2011). Treatment of multiple myeloma. Nat Rev Clin Oncol, 8, 479-91.
  14. Shaheen H, Ghanghroo I, Malik I (1999). Clinicopathological features and management of Pakistani patients with multiple myeloma. J Pak Med Assoc, 4, 233-7.
  15. Sashidharan N, Shenoy S, Kishore MK, Thanusubramanian H (2015). Comparison of two therapeutic regimes, lenalidomide with dexamethasone and thalidomide with dexamethasone, in the treatment of multiple myeloma at a tertiary care hospital in India. J Clin Diagn Res, 9, 1-4.
  16. Sun JJ, Zhang C, Zhou J, Yang HL (2015). Pooled analysis of pomalidomide for treating patients with multiple myeloma. Asian Pac J Cancer Prev, 16, 3163-6.
  17. Sutandyo N, Firna E, Agustina J, et al (2015). Clinicopathology profile and bone involvement of multiple myeloma patients in dharmais national cancer hospital, indonesia. Asian Pac J Cancer Prev, 16, 6261-5.
  18. Subramanian R, Basu D, Dutta TK (2009). Prognostic significance of bone marrow histology in multiple myeloma. Indian J Cancer, 46, 40-5.
  19. Vincent Rajkumar S (2014). Multiple myeloma: 2014 Update on diagnosis, risk-stratification, and management. Am J Hematol, 89, 999-1009.
  20. Wang L, Wang KF, Chang BY, Chen XQ, Xia ZJ (2015). Once-weekly subcutaneous administration of bortezomib in patients with multiple myeloma. Asian Pac J Cancer Prev, 16, 2093-8.
  21. Yassin AK (2013). Clinical and Laboratory Profiles of 109 Patients diagnosed as Multiple Myeloma in Erbil City. J Fac Med Baghdad, 55, 121-4.

Cited by

  1. Combined therapeutic effects of bortezomib and anacardic acid on multiple myeloma cells via activation of the endoplasmic reticulum stress response vol.14, pp.3, 2016,